- Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in bone diseasePlus news about Alebund Pharmaceuticals, Regenxbio and Neuphoria Therapeutics. 💸 A SPAC!: Talawar Therapeutics will land on the Nasdaq via a combination with blank-check company JATT II Acquisitio…Endpoints · 29d ago↗ source
- Post-Hoc: China deals are pharma’s new tax inversionsAbout a decade ago, when I had just started covering pharma, one of the biggest stories was tax inversions. For those who don’t remember, tax inversions were a form of M&A in which a US ...Endpoints · 29d ago↗ source
- Theravance, after clinical setbacks, agrees to $929M buyoutThe acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.